62 Laboratorievurderinger i kliniske forsøg har vist kortvarige stigninger i transaminaser og gammaglutamyltransferaser (bivirkningerne er dog ikke set statistisk signifikant hyppigere med Remeron sammenlignet med placebo).
In laboratory evaluations in clinical trials transient increases in transaminases and gamma- glutamyltransferase have been observed (however associated adverse events have not been reported statistically significantly more frequently with Remeron than with placebo).